IL17A and neoplasm: The potential threat to the clinical efficacy of immunotherapy posed by generation of excessive levels of IL-17A in the tumor microenvironment, both preceding and during anti-cancer chemotherapy, has been demonstrated in the clinical settings of the estrogen receptor-negative and triple-negative/basal-like subtypes of breast cancer (123, 124), thyroid cancer (125) and colorectal cancer (126).